Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 9/20 | 0.66 |
| ▸ | BTK | Q06187 | 2/20 | 0.59 |
| ▸ | IGF1R | P08069 | 9/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748832 | 0.91 | TNK2 (0.65) | TNK2BTKIGF1RCYP3A4MAPK3 | |
| SCHEMBL18099755 | 0.89 | BTK (0.65) | TNK2BTK | |
| SCHEMBL18099753 | 0.88 | TNK2 (0.64) | TNK2BTK | |
| SCHEMBL18099757 | 0.87 | TNK2 (0.64) | TNK2BTK | |
| SCHEMBL18099754 | 0.87 | TNK2 (0.62) | TNK2BTK | |
| SCHEMBL18099759 | 0.87 | BTK (0.62) | TNK2BTK | |
| SCHEMBL16748939 | 0.84 | TNK2 (0.65) | TNK2BTKIGF1RCYP3A4MAPK3 | |
| SCHEMBL18099756 | 0.84 | BTK (0.59) | TNK2BTK | |
| SCHEMBL18099752 | 0.82 | TNK2 (0.59) | TNK2BTK | |
| SCHEMBL16748846 | 0.81 | BTK (0.76) | TNK2BTKIGF1RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | TNK2 43/4885BTK 8/4885IGF1R 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.